Pyxis Oncology
Update in progressPYXS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Pyxis Oncology, Inc. is a clinical-stage company developing therapies for solid tumors. Its lead ADC, PYX-201, is in Phase 1 for relapsed or refractory solid tumors. Other programs include PYX-102, a KLRG1-targeting immunotherapy; PYX-106, a fully human IgG1 anti-Siglec-15 antibody in Phase 1; and PYX-107, a CD40 agonist in Phase 2. The company has licensing deals with Pfizer for ADCs and with Biosion USA for PYX-106. Headquartered in Boston, founded 2018.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Thomas Civik
- Founded2018
- Employees56
- Websitewww.pyxisoncology.com
Identifiers
- ISINUS7473241013
- FIGIBBG00PQFFCV5
- CUSIP747324101
- CIK0001782223